Payer Strategy That Builds Asset Value
BD-focused payer strategy advisory for emerging biotech leaders.
Access Navigate helps CEOs, CBOs, BD Heads, and investors pressure-test pricing, reimbursement, market access, evidence, and valuation assumptions before clinical, financing, partnering, licensing, acquisition, or launch decisions are locked.
We bring a pharma BD valuation lens to payer strategy, translating pricing and access dynamics into practical guidance for asset value, partner diligence, Phase 2/3 evidence planning, investor confidence, and deal readiness.
BD readiness
Strengthen investor narrative, support valuation discussions, and articulate clear price, access, and payer strategy.
Clinical planning
Define evidence needs, reduce reimbursement risk, and improve trial planning before decisions are locked.
Strategic focus
Build payer value, strategize access potential, and create a practical roadmap.
Our Mission
Many biotech teams with one to three Phase 1 to Phase 3 assets make critical development and valuation decisions before payer expectations are clear. Access Navigate helps these teams build fit-for-purpose payer strategy to support clinical development, BD partnering, investor confidence, and asset value.
Our Approach
Pharma BD insider perspective. Most payer research tells you what payers think. Access Navigate helps you apply what those payer views mean for asset value, BD diligence, clinical planning, and partner confidence.
Strategy first. Pressure-test second. We start with the asset value question, identify the payer assumptions most likely to affect BD confidence, then test the highest-risk opportunities and gaps with focused analog research, HTA learnings, payer input, clinician/KOL perspectives, and senior judgment.
Schedule a payer strategy discussion
Pressure-test your next BD, financing, or clinical milestone.